Premium
HOXD‐AS1 is a predictor of clinical progression and functions as an oncogenic lncRNAs in papillary thyroid cancer
Author(s) -
Xu Kai,
Feng Ying
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27809
Subject(s) - papillary thyroid cancer , cancer , thyroid cancer , cancer research , biology , oncology , medicine
Long noncoding RNA HOXD cluster antisense RNA 1 (HOXD‐AS1) has been found to play a crucial role in the tumorigenesis and progression of human cancer. However, the role of HOXD‐AS1 in papillary thyroid cancer is still unknown. The purpose of this study was to investigate the clinical value and biological function of HOXD‐AS1 in papillary thyroid cancer. The results showed HOXD‐AS1 is overexpressed in papillary thyroid cancer tissues and cell lines compared with matching nontumor tissue specimens and normal thyroid cell line, respectively. High expression of HOXD‐AS1 was associated with elderly people, advanced clinical stage, large tumor size, present lymph node metastasis, and distant metastasis. There was no significant correlation between HOXD‐AS1 expression and disease‐free survival or overall survival in this cohort from the TCGA database. The study in vitro suggested reduced HOXD‐AS1 expression inhibited papillary thyroid cancer cell proliferation, migration, and invasion, and promoted cell‐cycle arrest. In conclusion, HOXD‐AS1 is a biomarker for predicting clinical progression in papillary thyroid cancer.